Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study

Authors :: B. Hoen
P. Bourse
P. Leclercq
Lambert Assoumou
X. Rey-Coquais
J. P. Aboulker
P. Morlat
L. Chablais
J. M. Molina
C. Blanc
Claudine Duvivier
J. Reynes
V. Calvez
M. Shoai-Tehrani
F. Durand
P. Mercié
A. Makinson
F. Raffi
A. Canestri
C. Katlama
S. Gerberon
Gilles Peytavin
A. Cheret
A. Simon
S. Dominguez
C. Brochier
S. Scerra
J.-P. Bastard
Y. Dudoit
A.-S. Ritleng
I. Poizot Martin
S. Kolta
C. Soulié
S. Caldato
C. Lupin
Marc-Antoine Valantin
F. Touam
Y. Levy
N. Velazquez
O. Faucher
Minh Patrick Lê
S. Couffin Cadiergues
A G Marcelin
G. Pialoux
S. Bonne
V. Thoirain
J. Saillard
P. Geneau de la Marliere
Diane Ponscarme
Christine Katlama
C. Debreux
J. Capeau
M.-C. Marien
C. Crisol
K. Koffi
Vincent Calvez
H. Hue
H. Fisher
Cathia Soulié
L. Schneider
C. Lemarchand
L. Cotte
M.-J. Dulucq
C. Chesnel
D. Ponscarme
Anne-Geneviève Marcelin
L. Assoumou
Julie Chas
C. Haffner-Mauvais
C. Duvivier
L. Cuzin
Dominique Costagliola
J. Chas
Marc Antoine Valantin
Source :: Journal of Antimicrobial Chemotherapy. 70:2418-2420
Publication Year :: 2015
Publisher :: Oxford University Press (OUP), 2015.

Subjects :: Pharmacology
Microbiology (medical)
medicine.medical_specialty
business.industry
Raltegravir
Gastroenterology
Term (time)
chemistry.chemical_compound
Infectious Diseases
chemistry
Internal medicine
Plasma concentration
medicine
Pharmacology (medical)
In patient
Dual therapy
business
Maraviroc
medicine.drug

Tools